Point Therapeutics Provides Clinical Update During Recent Company Webcast; Additional Clinical Responses Observed In The Phase 2 Studies

BOSTON--(BUSINESS WIRE)--Feb. 2, 2006--Point Therapeutics, Inc. (NASDAQ: POTP) announced during a January 31, 2006 Webcast an additional clinical response in both its metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma combination Phase 2 studies.